Selection criteria to protect the blood donor in North America and Europe: past (dogma), present (evidence), and future (hemovigilance).

The safety of the blood supply depends on measures to protect not only the transfusion recipient but also the blood donor. Donor selection criteria have been voluntarily adopted or enforced through regulation in different countries, but review of practices in different blood centers reveals wide disparity in the current approaches. Such variability in practice suggests that the criteria for the protection of donor are often arbitrary or reflect deeply engrained precautionary practices and exposes the inherent uncertainty about the best way to minimize risk to the donor. Certain selection criteria introduced years ago have become dogma in some countries but were never subjected to systematic study and persist despite available evidence that the measures do not measurably improve donor safety. Current efforts to define a rational, evidence-based approach are crucial to eliminate practices that lead to the unnecessary deferral of large numbers of blood donors without improving the safety of the donation process. Future prospects to improve the safety of the donation process rest with hemovigilance initiatives to monitor the effectiveness of interventions to minimize the risks to blood donors.

[1]  L. Wadsworth,et al.  Reappraisal of optimal hemoglobin standards for female blood donors in Canada , 1994, Transfusion.

[2]  S. Deeks,et al.  Proceedings of a consensus conference: blood-borne HIV and hepatitis-optimizing the donor selection process. , 2003, Transfusion medicine reviews.

[3]  Tzong-Hae Lee,et al.  Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: frequent long-term microchimerism in severe trauma patients. , 1999, Blood.

[4]  B. H. Thiers Risk of cancer after blood transfusion from donors with subclinical cancer: a retrospective cohort study , 2008 .

[5]  R. Domen,et al.  Autologous Blood Donation by Patients with Cardiovascular Disease , 1992, Vox sanguinis.

[6]  C. Artlett Microchimerism in health and disease. , 2002, Current molecular medicine.

[7]  M. Popovsky,et al.  The safety of preoperative autologous blood donation in the nonhospital setting , 1991, Transfusion.

[8]  P. Tomasulo,et al.  A Study of Criteria for Blood Donor Deferral , 1980, Transfusion.

[9]  Christopher R France,et al.  Mild reactions to blood donation predict a decreased likelihood of donor return. , 2004, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[10]  S. Gabriel,et al.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. , 2008, Arthritis and rheumatism.

[11]  C. France,et al.  Mitigating adverse reactions in youthful donors , 2008, Transfusion.

[12]  QiupingGu,et al.  Antihypertensive Medication Use Among US Adults With Hypertension , 2006 .

[13]  E. Rimm,et al.  Blood Donations and Risk of Coronary Heart Disease in Men , 2001, Circulation.

[14]  Daniel W. Jones,et al.  Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. , 2005, Hypertension.

[15]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[16]  L. Chambers,et al.  Preoperative autologous blood donation. , 1990, Transfusion medicine reviews.

[17]  C. Vergin,et al.  THE EVALUATION OF BLOOD DONOR DEFERRAL CAUSES , 2006, Pediatric hematology and oncology.

[18]  J. Gillon,et al.  Consensus conference on autologous transfusion. Preoperative autologous donation , 1996, Transfusion.

[19]  F. Poles,et al.  SYNCOPE IN BLOOD DONORS , 1942 .

[20]  C. Danielson,et al.  Should cardiac disease prevent autologous blood donation? , 1997, Transfusion science.

[21]  H. Kolb,et al.  Transfer of diabetes type 1 by bone-marrow transplantation , 1998, The Lancet.

[22]  L. Murray-Kolb,et al.  Iron treatment normalizes cognitive functioning in young women. , 2007, The American journal of clinical nutrition.

[23]  C. Hillyer,et al.  Comparable safety of blood collection in "high-risk" autologous donors versus non-high-risk autologous and directed donors in a hospital setting. , 1994, American journal of clinical pathology.

[24]  D. Kessler,et al.  A question of clarity: redesigning the American Association Of Blood Banks blood donor history questionnaire--a chronology and model for donor screening. , 2007, Transfusion medicine reviews.

[25]  C. Fang,et al.  Donor deferral and resulting donor loss at the American Red Cross Blood Services, 2001 through 2006 , 2008, Transfusion.

[26]  E. Vamvakas,et al.  The Canadian blood donor health assessment questionnaire: lessons from history, application of cognitive science principles, and recommendations for change. , 2007, Transfusion medicine reviews.

[27]  B. Custer,et al.  The consequences of temporary deferral on future whole blood donation , 2007, Transfusion.

[28]  Ross Ward,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure , 2011 .

[29]  N. Shehata,et al.  Reaction rates in allogeneic donors , 2004, Transfusion medicine.

[30]  Kaaron Benson,et al.  Guide to the Preparation, Use and Quality Assurance of Blood Components , 1999 .

[31]  F. Boulton,et al.  Evidence‐based criteria for the care and selection of blood donors, with some comments on the relationship to blood supply, and emphasis on the management of donation‐induced iron depletion , 2008, Transfusion medicine.

[32]  J. Ward,et al.  Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV‐1 antibody screening , 1991, Transfusion.

[33]  G. Brittenham,et al.  Maintaining iron balance in women blood donors of childbearing age: summary of a workshop , 2002, Transfusion.

[34]  A. Farrugia,et al.  Iron and blood donation- an under-recognised safety issue. , 2007, Developments in biologicals.

[35]  K. Furie,et al.  Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2007, Circulation.

[36]  M. Goldman,et al.  Effect of changing the age criteria for blood donors , 2007, Vox sanguinis.

[37]  H. Kamel,et al.  Faint and prefaint reactions in whole‐blood donors: an analysis of predonation measurements and their predictive value , 2008, Transfusion.

[38]  C. Hillyer,et al.  The American Red Cross donor hemovigilance program: complications of blood donation reported in 2006 , 2008, Transfusion.

[39]  T. Wiltbank,et al.  The safety profile of automated collections: an analysis of more than 1 million collections , 2007, Transfusion.

[40]  K. Lewandrowski,et al.  Does blood donor history accurately reflect the use of prescription medications? A comparison of donor history and serum toxicologic analysis , 2006, Transfusion.

[41]  P J Garry,et al.  Iron stores in blood donors. , 1981, JAMA.

[42]  C. Hillyer,et al.  Adverse reactions to allogeneic whole blood donation by 16- and 17-year-olds. , 2008, JAMA.

[43]  B. Newman Blood donor complications after whole-blood donation. , 2004, Current opinion in hematology.

[44]  Atlanta,et al.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. , 2008, Arthritis and rheumatism.

[45]  D. Meyers,et al.  A historical cohort study of the effect of lowering body iron through blood donation on incident cardiac events , 2002, Transfusion.

[46]  B. Newman,et al.  Donor reactions in high‐school donors: the effects of sex, weight, and collection volume , 2006, Transfusion.

[47]  N. Blumberg,et al.  Incidence of adverse reactions in blood donors taking antihypertensive medications , 1982, Transfusion.

[48]  P. Lapuerta,et al.  Quantifying Risk of Adverse Clinical Events With One Set of Vital Signs Among Primary Care Patients with Hypertension , 2004, The Annals of Family Medicine.

[49]  R. Strauss Rationale for medical director acceptance or rejection of allogeneic plateletpheresis donors with underlying medical disorders , 2002, Journal of clinical apheresis.

[50]  J. Salonen,et al.  Body iron stores and the risk of coronary heart disease. , 1994, The New England journal of medicine.

[51]  W. Hitzler,et al.  [Preoperative autologous blood donation]. , 1990, Beitrage zur Infusionstherapie = Contributions to infusion therapy.

[52]  R. Cable,et al.  A case‐controlled multicenter study of vasovagal reactions in blood donors: influence of sex, age, donation status, weight, blood pressure, and pulse , 1999, Transfusion.

[53]  J. Löwer,et al.  The harmonization of the regulation of blood products: a European perspective , 2008, Vox sanguinis.

[54]  E. Beutler,et al.  The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? , 2006, Blood.

[55]  D. Halperin,et al.  The effect of short‐term, temporary deferral on future blood donation , 1998, Transfusion.